Compile Data Set for Download or QSAR
Report error Found 512 Enz. Inhib. hit(s) with Target = 'Tyrosine-protein kinase Blk'
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM50357312(IBRUTINIB | US9181263, 1 | US9108973, Ref 1 | US92...)
Affinity DataIC50: 0.100nMAssay Description:Inhibition of recombinant full length human His-tagged BLK cytoplasmic domain expressed in baculovirus expression system using tyrosine-1 peptide as ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/28/2022
Entry Details Article
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM50357312(IBRUTINIB | US9181263, 1 | US9108973, Ref 1 | US92...)
Affinity DataIC50: 0.100nMAssay Description:Inhibition of recombinant BLK (unknown origin) preincubated for 1 hr in presence of ATP by Z-Lyte assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
TBA
Entry Details
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM50357312(IBRUTINIB | US9181263, 1 | US9108973, Ref 1 | US92...)
Affinity DataIC50: 0.100nMAssay Description:Inhibition of BLK (unknown origin) incubated for 1 hr in presence of ATP by Z'LYTE assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/22/2024
Entry Details
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM50357312(IBRUTINIB | US9181263, 1 | US9108973, Ref 1 | US92...)
Affinity DataIC50: 0.100nMAssay Description:Inhibition of BLK (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM50455738(CHEMBL4211949)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of recombinant human BLK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details Article
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50: 0.200nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2016
Entry Details
US Patent

TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50: 0.200nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50: 0.200nMAssay Description:For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2025
Entry Details
US Patent

TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM13216(N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyeth...)
Affinity DataKd:  0.210nMAssay Description:Binding constant for BLK kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2012
Entry Details Article
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM13216(N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyeth...)
Affinity DataKd:  0.210nMAssay Description:Binding constant for BLK kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/25/2012
Entry Details Article
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM13216(N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyeth...)
Affinity DataKd:  0.210nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/22/2011
Entry Details
PCBioAssay
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM50357312(IBRUTINIB | US9181263, 1 | US9108973, Ref 1 | US92...)
Affinity DataIC50: 0.230nMAssay Description:Inhibition of human BLK using poly[Glu:Tyr] (4:1) as substrate preincubated for 60 mins followed by [gamma-33P]-ATP addition and measured after 120 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM50357312(IBRUTINIB | US9181263, 1 | US9108973, Ref 1 | US92...)
Affinity DataIC50: 0.230nMAssay Description:Inhibition of human BLK using poly[Glu:Tyr] (4:1) as substrate preincubated for 60 mins followed by [gamma-33P]-ATP addition and measured after 120 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM50357312(IBRUTINIB | US9181263, 1 | US9108973, Ref 1 | US92...)
Affinity DataIC50: 0.5nMAssay Description:Inhibition of BLK (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM50357312(IBRUTINIB | US9181263, 1 | US9108973, Ref 1 | US92...)
Affinity DataIC50: 0.5nMAssay Description:Inhibition of recombinant human BLK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details Article
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM50357312(IBRUTINIB | US9181263, 1 | US9108973, Ref 1 | US92...)
Affinity DataIC50: 0.5nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2016
Entry Details
US Patent

TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM50357312(IBRUTINIB | US9181263, 1 | US9108973, Ref 1 | US92...)
Affinity DataIC50: 0.5nMAssay Description:Inhibition of BLKMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/8/2013
Entry Details Article
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM50589186(CHEMBL5189379)
Affinity DataIC50: 0.5nMAssay Description:Inhibition of BLK (unknown origin) using peptide substrate in presence of ATP by caliper electrophoresis methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/18/2023
Entry Details
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM50357312(IBRUTINIB | US9181263, 1 | US9108973, Ref 1 | US92...)
Affinity DataIC50: 0.5nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
US Patent

TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM698784(US20240317756, Compound 1)
Affinity DataIC50: 0.5nMAssay Description:For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2025
Entry Details
US Patent

TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM538621(NCGC 00371481 | US11254667, Compound I-24 | US1154...)
Affinity DataIC50: 0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent

TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM538621(NCGC 00371481 | US11254667, Compound I-24 | US1154...)
Affinity DataIC50: 0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent

TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM139540(US8889696, Staurosporine | US9051313, Staurosporin...)
Affinity DataIC50: 0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent

TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM538618(NCGC 00262327 | US11254667, Compound I-20 | US1154...)
Affinity DataIC50: 0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent

TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM538619(NCGC 00371479 | US11254667, Compound I-22 | US1154...)
Affinity DataIC50: 0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent

TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM538619(NCGC 00371479 | US11254667, Compound I-22 | US1154...)
Affinity DataIC50: 0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent

TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM50357312(IBRUTINIB | US9181263, 1 | US9108973, Ref 1 | US92...)
Affinity DataKd:  0.560nMAssay Description:Binding affinity to BLK (unknown origin) assessed as dissociation constant by KINOMEscan analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/22/2023
Entry Details
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM50357312(IBRUTINIB | US9181263, 1 | US9108973, Ref 1 | US92...)
Affinity DataIC50: 0.580nMAssay Description:Preparation of Compounds to be Tested:1) Using DMSO to prepare 50× compound stock solutions (same as the stock solution in Example 34) for later use;...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/15/2021
Entry Details
US Patent

TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM50512346(CHEMBL4464404)
Affinity DataIC50: 0.700nMAssay Description:Inhibition of BLK (unknown origin) using STK as substrate by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/20/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM26145(CHEMBL249097 | 3-({4-[(5-hydroxy-2-methylphenyl)am...)
Affinity DataKd:  1nMAssay Description:Binding affinity to human BLKMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2010
Entry Details Article
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM250082(US9447106, 27b (peak 2) | US9556188, Compound 27a)
Affinity DataIC50: 1.10nMAssay Description:Inhibition of human BLK using poly[Glu:Tyr] (4:1) as substrate preincubated for 60 mins followed by [gamma-33P]-ATP addition and measured after 120 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM2579(CHEMBL388978 | Staurosporine, 8 | Staurosporin, 4 ...)
Affinity DataIC50: 1.10nMAssay Description:Inhibition of human BLK using poly[Glu:Tyr](4:1) as substrate by [gamma-33P]-ATP assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/19/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM2579(CHEMBL388978 | Staurosporine, 8 | Staurosporin, 4 ...)
Affinity DataIC50: 1.10nMAssay Description:Inhibition of human BLK using poly[Glu:Tyr](4:1) as substrate by [gamma-33P]-ATP assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details Article
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM250082(US9447106, 27b (peak 2) | US9556188, Compound 27a)
Affinity DataIC50: 1.10nMAssay Description:Inhibition of human BLK using poly[Glu:Tyr] (4:1) as substrate preincubated for 60 mins followed by [gamma-33P]-ATP addition and measured after 120 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM50357312(IBRUTINIB | US9181263, 1 | US9108973, Ref 1 | US92...)
Affinity DataIC50: 1.10nMAssay Description:Inhibition of BLK (unknown origin) by ADP-Glo assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2022
Entry Details Article
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM185674(Rebastinib | 4-[4-[(5-tert-butyl-2-quinolin-6-ylpy...)
Affinity DataIC50: 1.20nMAssay Description:Inhibition of human wild type BLK using PolyEY as substrate preincubated for 2 hrs followed by ATP addition and measured every 2 mins for 2.5 hrs by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
TBA
Entry Details
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM130909(US8822500, Stauro- sporine | US9920060, Staurospor...)
Affinity DataIC50: 1.20nMAssay Description:Inhibition of human BLK using poly[Glu:Tyr] (4:1) as substrate preincubated for 20 mins followed by [gamma-33P]-ATP addition and measured after 120 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
TBA
Entry Details
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM50614535(CHEMBL5271284)
Affinity DataIC50: 1.40nMAssay Description:Inhibition of BLK (unknown origin) by Z'LYTE assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/22/2024
Entry Details
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM6568(PD-173955 | CHEMBL386051 | 6-(2,6-dichlorophenyl)-...)
Affinity DataKd:  1.5nMAssay Description:Binding constant for BLK kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2012
Entry Details Article
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM452963(US10711006, Compound I)
Affinity DataIC50: 1.60nMAssay Description:Preparation of Compounds to be Tested:1) Using DMSO to prepare 50× compound stock solutions (same as the stock solution in Example 34) for later use;...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/15/2021
Entry Details
US Patent

TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM50589191(CHEMBL4114766)
Affinity DataIC50: 2.20nMAssay Description:Inhibition of BLK (unknown origin) using peptide substrate in presence of ATP by caliper electrophoresis methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/18/2023
Entry Details
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM50594746(CHEMBL5193128)
Affinity DataIC50: 2.5nMAssay Description:Inhibition of BLK (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM50020471(CHEMBL3290142)
Affinity DataIC50: 2.70nMAssay Description:Inhibition of Blk (unknown origin) after 1 hr by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/11/2015
Entry Details Article
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM4552(CHEMBL288441 | SKI-606 | 4-[(2,4-Dichloro-5-methox...)
Affinity DataKd:  3.30nMAssay Description:Binding constant for BLK kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2012
Entry Details Article
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM50357312(IBRUTINIB | US9181263, 1 | US9108973, Ref 1 | US92...)
Affinity DataIC50: 3.5nMAssay Description:Inhibition of N-terminal GST tagged BLK (1 to 505 end residues) (unknown origin) expressed in Sf21insect cells by time resolved fluorescence based as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2024
Entry Details
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM50020476(CHEMBL3290148)
Affinity DataIC50: 4.20nMAssay Description:Inhibition of Blk (unknown origin) after 1 hr by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/11/2015
Entry Details Article
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM473172(US10844038, Example 46 B. | (3R,4R)-3-((4-amino-3-...)
Affinity DataIC50: 5nMAssay Description:IC50 Table 13-20: The protocol calls for test compound of the invention to be incubated with kinase, substrate, cofactors, and radio-isotope-labeled ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2021
Entry Details
US Patent

TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM230107(US9334290, 32 | US10106559, Example 33 | US9850258...)
Affinity DataIC50: 5nMAssay Description:Inhibition of BLK (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/22/2022
Entry Details Article
PubMed
TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM473174(US10844038, Example 43 A. | (3S,4R)-3-((4-amino-3-...)
Affinity DataIC50: 5nMAssay Description:IC50 Table 13-20: The protocol calls for test compound of the invention to be incubated with kinase, substrate, cofactors, and radio-isotope-labeled ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2021
Entry Details
US Patent

TargetTyrosine-protein kinase Blk(Human)
Acerta Pharma

Curated by ChEMBL
LigandPNGBDBM452966(US10711006, Compound 15b)
Affinity DataIC50: 5.40nMAssay Description:Preparation of Compounds to be Tested:1) Using DMSO to prepare 50× compound stock solutions (same as the stock solution in Example 34) for later use;...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/15/2021
Entry Details
US Patent

Displayed 1 to 50 (of 512 total ) | Next | Last >>
Jump to: